Abstract:Background: With the emergence of new variants and sub-lineages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), reinfections can significantly impact herd immunity, vaccination policies, and decisions on other public health measures. We conducted a systematic review and meta-analysis to synthesise the global evidence on SARS-CoV-2 reinfections in the pre-Omicron era. Methods: We searched five global databases (MEDLINE, Embase, CINAHL Plus, Global Health, WHO COVID-19) on 12 May 2022 and 28 July 2023 and three Chinese databases (CNKI, Wanfang, CQvip) on 16 October 2022 for articles reporting incidence and outcomes of SARS-CoV-2 reinfection before the period of Omicron (B.1.1.529) predominance. We assessed risk of bias using Joanna Briggs Institute critical appraisal tools and conducted meta-analyses with random effects models to estimate the proportion of SARS-CoV-2 reinfection among initially infected cases and hospitalisation and mortality proportions among reinfected ones. Results: We identified 7593 studies and extracted data from 64 included ones representing 21 countries. The proportion of SARS-CoV-2 reinfection was 1.16% (95% confidence interval (CI) = 1.01-1.33) based on 11 639 247 initially infected cases, with ≥45 days between the two infections. Healthcare providers (2.28%; 95% CI = 1.37-3.40) had a significantly higher risk of reinfection than the general population (1.00%; 95% CI = 0.81-1.20), while young adults aged 18 to 35 years (1.01%; 95% CI = 0.8-1.25) had a higher reinfection burden than other age groups (children <18 years old: 0.57%; 95% CI = 0.39-0.79, older adults aged 36-65 years old: 0.53%; 95% CI = 0.41-0.65, elderly >65 years old: 0.37%; 95% CI = 0.15-0.66). Among the reinfected cases, 8.12% (95% CI = 5.30-11.39) were hospitalised, 1.31% (95% CI = 0.29-2.83) were admitted to the intensive care unit, and 0.71% (95% CI = 0.02-2.01) died. Conclusions: Our data suggest a relatively low risk of SARS-CoV-2 reinfection in the pre-Omicron era, but the risk of hospitalisation was relatively high among the reinfected cases. Considering the possibility of underdiagnosis, the reinfection burden may be underestimated. Registration: PROSPERO: CRD42023449712.

SARS-CoV-2 reinfection with Omicron variant in Shaanxi Province, China: December 2022 to February 2023

Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023

Omicron Variant Reinfection Risk among Individuals with Previous SARS-CoV-2 Infections Within One Year in Shanghai, China: A Cross-sectional Study

The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection Within One Year in Shanghai, China: A Cross-Sectional Study

A Follow-Up Study on the Recovery and Reinfection of Omicron COVID-19 Patients in Shanghai, China.

Incidence and outcome of SARS-CoV-2 reinfection in the pre-Omicron era: A global systematic review and meta-analysis

Genomic Surveillance for SARS-CoV-2 — China, September 26, 2022 to January 29, 2023

The serological IgG and neutralizing antibody of SARS-CoV-2 omicron variant reinfection in Jiangsu Province, China

Exploring the Transmission Dynamics of the COVID-19 Outbreaks after Dec. 2022 in Shaanxi Province, China: Analysis of Baseline Data from A Large Scale Cohort

Immune response and severity of Omicron BA.5 reinfection among individuals previously infected with different SARS-CoV-2 variants

Genomic epidemiology reveals early transmission of SARS-CoV-2 and mutational dynamics in Nanning, China

Characterizing Infections in Two Epidemic Waves of SARS-CoV-2 Omicron Variants: A Cohort Study in Guangzhou, China

Temporal Heterogeneous in the Effectiveness of Inactivated CoronaVac and Sinopharm Vaccines Against SARS-CoV-2 Reinfections in China

Evaluating the risk of SARS-CoV-2 reinfection with the Omicron or Delta variant in Wales, UK

Analysis of Re-Infection Cases and Influencing Factors Post First Severe COVID-19 Wave in Jiangsu Province, China

Clinical and Virological Characteristics of SARS-CoV-2 Omicron BA.2.2 Variant Outbreaks During April to May, 2022, Shanghai, China

Trends of SARS-CoV-2 Infection in Rural Area in Sentinel Community-Based Surveillance — China, December 2022 to January 2023

Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis

Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing

[Epidemiological characteristics of COVID-19 in Shaanxi province].

The symptoms and interval of Omicron SARS-CoV-2 reinfection among healthcare workers in a hospital of Southern China: a cross-sectional study